The online version of this article (doi:10.1186/1757-1146-7-9) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests. The study was supported by a grant of VGHKS100-061 (an academic research fund from the hospital’s medical research council).
All authors contributed to the conception and design of this research. SS, YC, JC and JW performed the experiments. YC provided participants, JC and JW performed patient follow-up. HL and CH performed the statistical analysis. SS and CH interpreted data and drafted the manuscript. All authors read and approved the final manuscript.
There was an increasing requirement for novel treatments of osteoarthritis (OA). The aim was to compare the efficacy of intraarticular Botulinum toxin type A (BoNT-A) and intraarticular hyaluronate plus rehabilitation exercise in patients with ankle OA.
This was a prospective, randomized, assessor-blinded study with a 6-month follow-up period, conducted in the outpatient rehabilitation department at a university-affiliated tertiary care medical center. Seventy-five patients with symptomatic ankle OA (Kellgren-Lawrence grade 2) were randomized to receive either a single 100-unit BoNT-A injection into the target ankle (n = 38) or a single hyaluronate injection plus 12 sessions of rehabilitation exercise (30 minutes/day, 3 times/week for 4 weeks) (n = 37). The primary outcome measure was the Ankle Osteoarthritis Scale (AOS). Secondary outcome measures included American Orthopedic Foot and Ankle Society (AOFAS) Ankle/Hindfoot Score, visual analog scale (VAS) for ankle pain, single leg stance test (SLS), Timed “Up-and-Go” test (TUG), consumption of rescue analgesics and global patient satisfaction.
There were no significant between-group differences in total AOS scores, pain subscale and disability subscale scores (adjusted mean difference AMD = -0.2, 95% CI = (-0.5, 0.2), p = 0.39; AMD = -0.1, 95% CI = (-0.5, 0.3), p = 0.57; AMD = -0.2, 95% CI = (-0.6, 0.2), p = 0.36). The 2 groups showed no significant differences in AOFAS, VAS, SLS, TUG scores and consumption of rescue analgesics at each follow-up visit, except that the hyaluronate group improved more in SLS than the BoNT-A group at 1-month follow-up. Patients’ satisfaction rate was high, with no serious adverse events. There was no difference in adverse events between the two groups (p = 1.00).
Treatment with intraarticular BoNT-A or hyaluronate injection plus rehabilitation exercise was associated with improvements in pain, physical function and balance in patients with ankle OA. These effects were rapid at 2 weeks and might last for at least 6 months. There was no difference in effectiveness between the two interventions.
The trial was registered at clinical trials.gov (Registry number NCT01760577).
Mense S: Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004, 251 (1): 11-17. 10.1007/s00415-004-0321-7. CrossRef
Frizziero L, Govoni E, Bachin P: Intraarticular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Clin Exp Rheumatol. 1998, 16: 441-449. PubMed
Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, Zummer M: The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995, 3: 213-225. 10.1016/S1063-4584(05)80013-5. CrossRefPubMed
Witteveen AGH, Giannini S, Guido G, Jerosch J, Lohrer H, Vannini F, Donati L, Schulz A, Scholl J, Sierevelt IN, van Dijk CN: A prospective multi-centre, open study of the safety and efficacy of hylan G-F 20 (Synvisc) in patients with symptomatic ankle (talo-crural) osteoarthritis. Foot Ankle Surg. 2008, 14: 145-152. 10.1016/j.fas.2008.01.001. CrossRefPubMed
Dworkin DH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, et al: Consensus statement: interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008, 9: 105-121. 10.1016/j.jpain.2007.09.005. CrossRefPubMed
Konttinen YT, Kemppinen P, Segerberg M, Hukkanen M, Rees R, Santavirta S, Sorsa T, Pertovaara A, Polak JM: Peripheral and spinal neural mechanisms in arthritis, with particular reference to treatment of inflammation and pain. Arthiritis Rheum. 1994, 37: 965-982. 10.1002/art.1780370701. CrossRef
Fisher NM, Pendergast DR: Reduced muscle function in patients with osteoarthritis. Scand J Rehabil Med. 1997, 29: 213-221. PubMed
- Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II